Cerebral Therapeutics is a clinical-stage biopharmaceutical company pioneering intracerebroventricular (ICV) drug delivery via a proprietary implanted infusion system. Its lead investigational therapy, CT-010, is being developed to treat uncontrolled seizures in patients with medically refractory epilepsy. The company’s drug-device combination aims to increase targeted brain exposure, reduce systemic drug exposure, and improve safety and adherence. Cerebral plans to use the new financing to complete an international Phase 2 double-blind, randomized, placebo-controlled trial of CT-010 and to support Phase 3 readiness. Proceeds will also advance the broader ICV therapies pipeline, including internal programs and collaborations with biopharmaceutical partners. The company emphasizes a biomarker strategy and says its platform is suitable for small molecules, oligonucleotides, antibodies, and enzyme therapies. Cerebral Therapeutics develops drug-device combination therapies that deliver therapeutics directly to the central nervous system via a proprietary implanted intracerebroventricular (ICV) infusion system. Its lead investigational product, CT-010, is being developed to treat uncontrolled seizures in adults with medically refractory epilepsy. The company reports emerging Phase 2a data suggesting direct brain administration of CT-010 may dramatically reduce seizure burden. Cerebral plans to use Series B proceeds to initiate an international Phase 2b double-blind, randomized, placebo-controlled trial of CT-010. The ICV approach is intended to increase brain exposure, reduce systemic drug exposure, improve safety, and enhance therapy adherence. The company is clinical-stage and focused on severe refractory epilepsy and other uncontrolled neurological diseases. Cerebral Therapeutics is developing reformulated drugs that bypass the blood–brain barrier using chronic implantable infusion systems to improve outcomes for patients with medically refractory epilepsy. The company is conducting a proof-of-concept study in adult patients at the University of Melbourne using a proprietary intracerebroventricular (ICV) formulation of an anti-epileptic drug, which has shown potentially enhanced efficacy and reduced toxicity. Led by Dan Abrams, M.D., CEO, Cerebral plans to use the financing proceeds to file an IND with the U.S. Food and Drug Administration and initiate a Phase 2 clinical trial. The company closed a $7.8m Series A extension, bringing total Series A investment to $11m. Backers in the extension included Granite Point Capital Management and Vivo Capital. Cerebral is based in Aurora, Colo. Cerebral Therapeutics is an Aurora, Colo.-based clinical-stage company focused on implanted drug-device combination therapies to improve the lives of patients with uncontrolled neurological diseases. Led by Dan Abrams, M.D., the company’s initial focus is refractory epilepsy. It is developing long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver specially formulated neurological therapeutics directly into target regions of the brain. Cerebral Therapeutics is currently exploring direct intracerebroventricular (ICV) administration of a proprietary formulation of an anti-epileptic drug to potentially enhance efficacy and reduce toxicity in adult patients with refractory epilepsy. The company closed a $3M Series A financing led by Granite Point Capital Management and Vivo Capital. In conjunction with the financing, Warren Lammert, Mahendra G. Shah, and Stephen J. Farr joined the board, and Andre Cheng will join as a board observer. As a clinical-stage company, its near-term focus is advancing its implanted delivery program through clinical development.

Total raised

$86M

Funding rounds

4

Latest round

Series C

Latest activity

Jun 2022